SuperworthLineage Cell Therapeutics market cap LCTX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $252.9M
- Highest close in our data
- $475.6M
- Apr 2015
Lineage Cell Therapeutics is worth $252.9M at the close on Oct 23, 2026, at $1.00 a share.
That is down 35% over the last year and down 34% over five years.
Its highest close in our data was $475.6M in Apr 2015.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $252.9M | $235.3M | $460.8M | −33% |
| 2025 | $380M | $93.6M | $438.4M | +305% |
| 2024 | $93.9M | $93.9M | $279M | −51% |
| 2023 | $190.7M | $159.3M | $258.4M | −4% |
| 2022 | $198.9M | $181.6M | $333.7M | −52% |
| 2021 | $413M | $277.5M | $467.2M | +56% |
| 2020 | $264M | $107.9M | $264M | +129% |
| 2019 | $115.3M | $89.1M | $258.4M | −4% |
| 2018 | $120.6M | $109.2M | $366.6M | −56% |
| 2017 | $272.8M | $272.8M | $398M | −27% |
| 2016 | $373.2M | $204M | $403.2M | −4% |
| 2015 | $389.1M | $214M | $475.6M | +24% |
| 2014 | $314.2M | $163.6M | $314.2M | +32% |
| 2013 | $237.2M | $162.8M | $268.1M | +48% |
| 2012 | $160.7M | $155.2M | $299M | −45% |
| 2011 | $291.9M | $203.3M | $291.9M | n/a |
Against its peers
Companies in Biotechnology nearest Lineage Cell Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| LCTXLineage Cell Therapeutics | $252.9M |
| PLXProtalix BioTherapeutics | $205.5M |
| MGTXMeiraGTx | $884.6M |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| Peer median | $1.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Lineage Cell Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.